PIK3CA and breast carcinoma: Additionally, the recent phase III SOLAR1 trial reported a significant improvement in progression-free survival for breast cancer patients harboring PIK3CA mutations when treated with BYL719 (p110α inhibitor) plus fulvestrant (ER degrader)14,26–28.